Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9343956 | 0.89 | TDP1 (0.40) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9345135 | 0.88 | MEN1 (0.56) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348521 | 0.81 | MEN1 (0.39) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348882 | 0.81 | MEN1 (0.41) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9348888 | 0.81 | MEN1 (0.41) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9345597 | 0.81 | MEN1 (0.50) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| SCHEMBL9345173 | 0.79 | KMT2A (0.40) | MEN1KMT2AALOX15CYP2C19HSD17B10 | |
| Acetic Acid SCHEMBL27782836 | 0.76 | SRR (0.51) | SCN9A | |
| Hydrochloric Acid SCHEMBL27782844 | 0.76 | SRR (0.54) | SCN9A | |
| SCHEMBL132790 | 0.74 | ALPI (0.61) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-5321016-A | Epliepsy, central nervous system disorders | SANDOZ PHARMACEUTICALS CORP. (US) | 1994-06-14 | — | — | US | disclosed |
| US-5162311-A | Treating epilepsy, psychiatric disorders | SANDOZ PHARMACEUTICALS CORP. (US) | 1992-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | MEN1 1615/4885KMT2A 2257/4885ALOX15 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.